ArticleFrontiers in immunology2025

Engineering HER2-targeted biparatopic antibodies to promote receptor internalization and restore antitumor efficacy.

Xinlin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.